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Background: CEA is expressed in >90% of pancreatic cancers (PC) and may be an appropriate immunotherapy
target. CEA is poorly immunogenic due to immune tolerance; CAP1-6D, an altered peptide ligand can help bypass
tolerance. We conducted a pilot randomized phase I trial in PC patients to determine the peptide dose required to
induce an optimal CD8+ T cell response.
Methods: Patients with a PS 0-1, HLA-A2+ and CEA-expressing, previously-treated PC were randomized to receive
10 μg (arm A), 100 μg (arm B) or 1000 μg (arm C) of CEA peptide emulsified in Montanide and GM-CSF, given every
2 weeks until disease progression.
Results: Sixty-six patients were screened and 19 enrolled of whom 14 received at least 3 doses of the vaccine and
thus evaluated for the primary immunologic endpoint. A median of 4 cycles (range 1-81) was delivered. Median
and mean peak IFN-γ T cell response by ELISPOT (spots per 104 CD8+ cells, Arm A/B/C) was 11/52/271 (A vs. C,
p = 0.028) for medians and 37/148/248 (A vs. C, p = 0.032) for means. T cell responses developed or increased in
20%/60%/100% of pts in Arms A/B/C. Seven of the 19 patients remain alive at a minimum 32 months from trial
initiation, including three with unresectable disease.
Conclusions: The T cell response in this randomized phase I trial was dose-dependent with the 1 mg CEA peptide
dose eliciting the most robust T cell responses. A signal of clinical benefit was observed and no significant toxicity
was noted. Further evaluation of 1 mg CEA peptide with stronger adjuvants, and/or combined with agents to
overcome immune inhibitory pathways, may be warranted in PC pts.
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Pancreatic cancer (PC) is a devastating disease. With an
estimated annual incidence of 43,920 in the United
States in 2012, it is the fourth leading cause of cancer
mortality with 37,390 deaths annually [1]. Currently, the
only possibility of cure is through surgical resection, but
only approximately 15%–20% of patients are eligible
candidates at diagnosis and even with surgery the 5-year
overall survival in multiple series is 10%-30% [2]. In
those with locally advanced or unresectable disease
(~30%–40% of patients) the median overall survival (OS)
has been between 8 and 14 months. Patients with meta-
static disease (~40%) had a historical median OS of ap-
proximately 6 months, although recently substantial
progress has been made in chemotherapy options for
these patients [3].
Due to the inherent chemotherapy- and radiation-
resistance of pancreatic cancer cells, immunotherapy has
been explored as a treatment modality in PC patients
since the 1990s with a recent review focused on this
topic [4]. Multiple vaccination platforms have been
developed and tested in advanced solid malignancies
including PC, both in metastatic and adjuvant settings.
Most of the vaccination techniques have focused on
promoting a tumor antigen-specific T cell response using
either vaccination or adaptive transfer of tumor-specific
T cells in order to increase immune-mediated tumor
inhibition [5]. Identification of specific tumor-associated
antigens (TAAs) in PC has led to numerous trials of vac-
cination with these peptides as this approach is safe and
relatively simple [6-13]. The goal of this technique is to
elicit a CD8+ cytolytic T lymphocyte (CTL) response
that is specific for the TAA and subsequent killing of
tumor cells harboring that antigen by those CTLs.
An example of a TAA, carcinoembryonic antigen
(CEA), is a 180-kDa immunoglobulin-like molecule that
is expressed on the cell surface, is overexpressed in over
90% of pancreatic adenocarcinoma and functions in
cellular adhesion [12,14,15]. CEA as a self-protein has
been shown to be poorly immunogenic and thus modifi-
cations have been made to enable better binding to the
MHC-I complex. CAP-1 (YLSGANLNL), an epitope of
CEA, was further modified to CAP1-6D (an Asn to Asp
substitution in the CEA sequence; YLSGADLNL), and is
an enhanced agonist peptide binding to HLA-A2. Via a
change in the interaction with the T cell receptor it pro-
duces a more potent CTL response and T cells generated
via this approach have been shown to be cross-reactive
with wildtype CAP1 and to recognize CEA+ HLA-A2+
tumor cells [16,17].
A number of trials have employed the CEA TAA in
various vaccination platforms for patients with CEA-
expressing tumors. The early trials showed that the ap-
proach was safe in various platforms and with GM-CSFas an adjuvant [18-21]. In the trials which incorporated
CEA as an antigen, only one to our knowledge was
conducted and reported exclusively in PC patients [22].
In that phase I study, a poxvirus targeting CEA and
MUC-1 along with B7.1, ICAM-1 and LFA-3 (TRICOM)
(PANVAC-V) was administered followed by booster
vaccinations using PANVAC-F (fowlpox virus with same
antigens) as well as GM-CSF in ten advanced PC
patients. They noted an antibody response in all 10
patients and antigen-specific T cell responses in 5 out of
8 evaluable subjects. A significant increase in OS was
observed in those who mounted an anti-CEA and/or
MUC-1 response (15.1 m vs. 3.9 m; P = 0.002). Several
other studies used CEA vaccination alone or with other
epitopes such as MUC-1, with or without radiotherapy
and with various platforms, but most patients in those
trials did not have PC [23-27]. In general, the vaccines
were all safe, elicited an immunologic response in a
significant number of patients, and led occasionally to
sustained clinical responses.
Given the above considerations, we believed it was
desirable to explore further CEA-based vaccination in
PC patients. To eliminate the necessity of obtaining
patient-specific DCs, we utilized tumor antigen peptide
emulsification in Montanide adjuvant along with GM-CSF,
which has been suggested to stimulate DC differentiation
and improve DC recruitment [28,29]. Because the appro-
priate dose of a CEA-based vaccine to elicit the most robust
response was unknown, we designed a randomized phase I
study to determine the most appropriate peptide dose. This
approach would enable us to ascertain whether an immune
response could be elicited, and could establish the most ef-
fective dose of the CEA peptide within the vaccine formula-
tion to use in further trials. We report the results of this
randomized phase I pilot trial of a CAP1-6D/Montanide/




The study was designed as a randomized pilot trial with
the primary endpoint to determine the dose of modified
carcinoembryonic antigen (CEA) peptide (CAP1-6D)/
Montanide/GM-CSF-vaccine required to induce an opti-
mal CD8+ T cell response and to determine whether this
response can be assessed by ELISPOT. Defining the dose
limiting toxicities (DLTs), progression free survival and
median overall survival were secondary endpoints. The
laboratory objective was to determine whether this
immunization elicits a specific T cell response as
assessed by IFN-γ ELISPOT, against both the CAP1-6D
and the native peptide. The study was approved by the
University of Chicago Institutional Review Board and
conducted at the University of Chicago. All patients
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cordance with federal, state, and institutional guidelines.
Eligibility
Patients were required to have an Eastern Cooperative
Oncology Group performance status of 0 or 1 and
adequate hematologic, hepatic, and renal function. Al-
though originally designed to include only those treated
definitively with no evidence of disease (NED) or those
with locally advanced PC, the inclusion was later ex-
panded to allow for those with metastatic PC in order to
improve accrual. Eligible patients must have expressed
HLA-A2 and have histologically or cytologically con-
firmed adenocarcinoma of the pancreas that expresses
CEA either by IHC or serology. Life expectancy of over
3 months, no systemic treatment within 28 days of trial
initiation (6 weeks for nitrosoureas or mitomycin C), and
age of 18 or older were also required. Exclusion criteria
included previous CEA vaccine; history of allergic reaction
to compounds of similar chemical or biologic composition
to CEA, Montanide ISA-51 or GM-CSF; known auto-
immune disorders; conditions of immunosupression such
as HIV or treatment with immunosuppressive drugs;
pregnancy or breast-feeding; currently active second
malignancy; and uncontrolled intercurrent illness.
Vaccine formulation and treatment plan
The vaccine contained the modified CEA peptide
(CAP1-6D; YLSGADLNL; Multiple Peptide Systems, San
Diego, CA) together with Montanide ISA-51 (Seppic, Inc.)
as an adjuvant, and sargramostim (GM-CSF; purchased
commercially) 250 μg. Vaccine emulsions were prepared
in the University of Chicago cGMP facility. Briefly, the ap-
propriate dose of CEA peptide was thawed, combined
with 0.9 ml of sterile saline and mixed with GM-CSF and
Montanide ISA-51 using the two-syringe method to make
an emulsion. To verify creation of an emulsion, a drop
was placed in a dish of sterile water and if the drop did
not disperse, the emulsion was considered to be a success.
Patients were seen for a baseline evaluation which in-
cluded a history and physical, CT/MRI, blood chemis-
tries, complete blood count with differential, and HLA
typing. Confirmation of CEA expression was established
either by IHC on the original tumor or by elevated
serum CEA levels. Only subjects positive for HLA-A2
and with evidence for CEA expression continued on the
study. A cycle was defined as 14 days and vaccine was
administered on Day 1 of each cycle until progressive
disease or dose-limiting toxicity for a maximum of 24
cycles with delays of greater than 28 days leading to
study withdrawal. The vaccine administration site was
the proximal thigh with each subsequent administration
in the same approximate location. Following the initial
administration, patients were seen prior to each vaccineadministration with ELISPOT and CA19-9 performed
every 4 weeks for the first 8 cycles and a CT/MRI every
8 weeks. After the eighth cycle, CT/MRI and CA 19-9
was repeated every 8 weeks thereafter for one year until
disease progression or DLT with ELISPOT performed at
the time of disease progression. After one year, CT scans
were done every 16 weeks for one year, followed by every
6 months for one year and then annually until progression
of disease.
Response criteria and toxicity
Clinical response was evaluated using the Response
Evaluation Criteria in Solid Tumors v1.0 [30]. Dose-
limiting toxicity was defined as Grade 2 or greater
hemorrhage or allergic reaction; any other Grade 3 or
greater toxicity or clinical evidence of autoimmune
disease. All adverse events were graded according to the
CTCAE v2.0.
Collection of peripheral blood mononuclear cells (PBMCs)
and preparation of CD8+ T cells
Heparinized blood was drawn before treatment, monthly
during the vaccination period, and at the end of study.
Samples were collected prior to a given treatment ad-
ministration. PBMCs were isolated using Lymphoprep
gradient centrifugation and cryopreserved for immune
assays. CEA-specific CD8+ CTL responses were tested
by IFN-γ ELISPOT, against both the modified CEA
(CAP1-6D) and the wild-type peptide. Poor CEA-
specific CD8+ CTL responses were detected by a direct
ex vivo assay, so a short in vitro expansion was
performed. Briefly, PBMCs were thawed and washed
twice with PBS. CD8+ T cells were isolated using anti-
CD8 micro beads (Miltenyi Biotech). The non-CD8+
population was pulsed with modified CEA peptide (50
μM) at the presence of β2-microglobulin for 1 hour at
37˚C. The cells were then washed twice with AIM-V
media and irradiated at 3000 rad. Purified CD8+ T cells
were stimulated with irradiated peptide-pulsed CD8-
cells along with IL-2 (10 U/ml) for 5 days. On day 5, the
CD8+ T cells were collected and re-stimulated with
freshly prepared irradiated peptide-pulsed CD8- cells
and IL-2 (10 U/ml) for another 5 days. On day 10, the
expanded CD8+ T cells were collected, counted, and re-
stimulated with peptide-loaded T2 cells for IFN-γ
ELISPOT analysis.
ELISPOT assay
Briefly, 96 well multiscreen filter plates were prepared by
coating overnight with anti-INF-γ mAb (10 μg/ml),
washing 3× with PBS, and blocking 1 hour with AIM-V
medium containing 10% human AB serum. Expanded
CD8+ T cells (10,000/well) were added along with T2
cells (50,000/well) previously loaded with wild type CEA
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a G250 negative control peptide (50 μM each). Following
a 20 hour culture, wells were washed 3 times with
ELISPOT wash buffer, incubated 2 hours with a
biotinylated anti-IFN-γ secondary Ab, washed 3 times,
incubated 1 hour with streptavidin-conjugated AP,
washed, and incubated with AP substrate. Excess sub-
strate was removed by rinsing with tap water. Plates
were captured and counted using a CTL-ImmunoSpot
S6 Core Analyzer from Cellular Technology Ltd (Cleve-
land, OH). Stimulation with PMA + Ionomycin was used
as a positive control for the integrity of the T cell sam-
ples. All samples were analyzed in triplicate, and the
mean response to the G250 negative control was
subtracted from each sample. A positive ELISPOT re-
sponse for a patient was defined as a minimum increase
from baseline in a CTL ELISPOT assay by 50 CEA spots/
1×104 CD8+ T cells and a 20% increase over baseline:
[(peak ELISPOT-baseline ELISPOT)/baseline ELISPOT] ×
100 ≥ 20% and a peak ELISPOT ≥ 50 spots.
Statistical considerations
Patients were randomized into one of three dose levels.
A sample size of 15 evaluable patients was planned to
obtain sufficient T cell response data in each cohort. The
sample size was based on a recombinant avipox vaccine
study by von Mehren et al. in patients with recurrent
CEA-expressing adenocarcinomas [24]. Acceptable tox-
icity was defined as a DLT observed in no more than 20%
of patients at a given dose.
To be included in the analysis a patient must have had
a baseline ELISPOT and then at least 3 cycles of the
vaccine with an additional ELISPOT done after the 3rd
cycle. The maximum T cell frequency achieved was used
in the calculation. Descriptive statistics were used to
describe the characteristics of the study population.
Data was analyzed for overall survival and progression
free survival using the Kaplan-Meier estimates from the
start of treatment and comparison between the treatment
arms using the log-rank test. Elispot responses were
compared using Mann–Whitney Rank Sum Test with a P
value based on a two-tailed test and P < 0.05 considered
statistically significant. Univariate Cox regression models
examining CA19-9 levels, ELISPOT and stage (metastatic
vs. non-metastatic) were done for PFS and OS.
Results
Patient characteristics
Sixty-six patients were screened, twenty-three enrolled,
and nineteen received at least a single dose of the
vaccine (Figure 1). Patients were randomized to receive
10 μg (arm A), 100 μg (arm B) or 1000 μg (arm C) of
peptide in the vaccine preparation. Forty-three subjects
were screen failures: 36 due to lack of HLA-A2expression, four for withdrawing of consent, one for in-
correct pathology, one for lack of CEA expression by
IHC, and one for an elevated bilirubin. Nineteen patients
received at least one dose of the vaccine; three patients
experienced a declining performance status and one had
a gastrointestinal bleed prior to administration of any
vaccine. Fourteen patients received at least three doses
of the vaccine and were eligible for the primary im-
munologic endpoint: 5 in arm A, 5 in arm B and 4 in
arm C. The overall and per-group patient characteristics
are listed in Table 1. Sixty-eight percent of patients were
female. The median age was 60 (range 27–86) and 53%
had an ECOG performance status 0. Three-quarters had
metastatic disease, with all but one of the remaining
patients having no evidence of disease at the time of
enrollment.
A total of 256 cycles were delivered (median 4, mean,
13.5, range 1–81). The initial protocol did not specify a
maximum number of cycles and this was amended after
the first patient received 81 cycles, at which time the
number of cycles was limited to 24. No dose reductions
were allowed nor did any occur.
Immunologic response
A positive CD8+ T cell response to CAP1-6D developed
in 20% of patients in Arm A, 60% of patients in Arm B,
and 100% of patients in Arm C. Five patients were not
able to be assessed immunologically due to either less
than 3 cycles of the vaccine administered (one patient)
or for incomplete sample collection due to early disease
progression (4 patients). The mean/median CAP1-6D
CD8+ T cell response by ELISPOT in the 14 evaluable
patients (spots per 104 CD8+ cells) was 36.5/10.5 in Arm
A, 148.45/51.75 in Arm B and 247.69/270.625 in Arm C
(Figure 2). A statistically significant difference in median
(P = 0.028) and mean (P = 0.032) T cell response against
the immunizing mutant peptide was observed between
arm A and C. T cell responses to the wild-type CEA pep-
tide followed a similar pattern and also were statistically
significantly different between arm A and C (P = 0.028)
(Figure 2). The kinetics of the magnitude of the T cell re-
sponses were tracked over time for all 14 patients stratified
by treatment arm (Figure 3). In general, the peak immune
response appeared to occur within the first 100 days and
diminished thereafter. In the two of the three patients
receiving the vaccine for over 4 months the response was
still sustained and remained detectable.
Response and survival
Individual clinical responses for all 19 patients are listed
in Table 2. Seven patients (37%) had stable disease (SD)
as their best response and all remain alive today. Among
the 14 immunologically evaluable patients, eight had a
positive ELISPOT response of which 4 had progressive
Figure 1 Study Enrollment and Treatment. CONSORT Diagram.
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their best response. Among the 6 patients failing to exhibit
positive ELISPOT response, 2 had PD and 4 SD as their
best response. There was one CR in a patient with locally
advanced, unresectable PC. This patient underwent
chemotherapy and radiation and then received 81 doses of
the vaccine, randomized to Arm C. She developed a
strong ELISPOT response and remains alive and disease
free at over 75 months. One patient with metastatic PC in
Arm B had SD for 11 months (22 cycles of vaccine admin-
istered), a strong CTL response and is alive at over 43
months. Another patient with metastatic PC in Arm C
had SD for 6 months, a strong CTL response and is alive
at over 48 months. Of the 5 patients that were not able to
be evaluated for immunologic response, 3 were in Arm B
and 2 in Arm C (Table 2). All 5 had PD within less than 2
months and all died shortly thereafter. Eleven patients had
progressive disease (PD) as their best response at or prior
to their first scheduled CT evaluation at 8 weeks.
The median OS for the entire cohort of 19 patients was
334 days with a median PFS of 56 days. Overall, 7/19patients (37%) were alive at a minimum 32 months from
trial initiation and of the 17 patients with LA or metastatic
disease, five (29%) remain alive. The study was not
powered to detect differences in clinical outcome between
the three cohorts.Toxicity
All 19 patients were evaluable for toxicity. No grade 4
and 5 toxicities were observed; grade 1-3 toxicities are
summarized in Table 3. No discontinuation of treatment
occurred due to toxicity and no grade 2 or greater
hemorrhage or allergic reaction occurred; no auto-
immune disorders were noted. The most common
toxicities were grade 1-2 skin reactions to the vaccine
injection. These did not develop differentially in re-
sponders versus non-responders and did not correlate
with ELISPOT results. Otherwise common side effects
of pain, fatigue, anorexia, nausea/vomiting, diarrhea and
constipation were felt to be due to primary disease and
not the study vaccine.












Total 19 5 8 6
Age
Median 60 51 57.5 61.5
Range 27–86 27–71 50–86 47–77
Sex
Male 6 (32) 1 (20) 4 (50) 1 (17)
Female 13 (68) 4 (80) 4 (50) 5 (83)
ECOG Performance
Status
0 10 2 4 4
1 9 3 4 2
Stage at Trial Entry
No evidence of
disease
4 (21) 2 (40) 0 (0) 2 (33)
Locally advanced 1 (5) 0 (0) 0 (0) 1 (17)




5 1 3 1
Chemotherapy/RT
alone
2 0 1 1
Surgery total 12 4 4 4
Surgery followed
by chemotherapy
7 3 2 2





Yes 12 (63) 4 (80) 4 (50) 4 (67)
No 7 (37) 1 (20) 4 (50) 2 (33)
Serum CEA at trial
initiation (ng/mL)
Median 4.8 5.3 4.65 7.95
Range 1–246.7 1.1–34.2 2.1–246.7 1–18.1
Serum CA-19-9 at trial
initiation (ng/mL)
Median 532 22 1067 27
Range 3–96,900 3–2,710 3–96,900 3–30,300
Abbreviation: Chemo/RT = chemotherapy in combination with radiation;
* All received previous chemotherapy.
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The diagnosis of pancreatic cancer is associated with ap-
proximately a 5-year survival rate of 6% [1]. Innovative
therapies are thus desperately needed. Immunotherapy
via vaccination has been one approach investigated over
the last decade. In pancreatic cancer, several trials have
shown that use of a TAA such as MUC-1 in combinationwith CEA or K-Ras can elicit an immunologic response
and possibly improve outcomes in those mounting such
a response. To our knowledge, no other trial reported
has used CEA as the exclusive TAA vaccination plat-
form in a strictly PC population and the optimal dose of
such a vaccine was unknown. The primary objective of
this study was to determine the optimal dose of the
carcinoembryonic antigen (CEA) peptide (CAP1-6D)/
Montanide/GM-CSF-vaccine amongst the three doses
administered to induce a maximal CTL response in pa-
tients with pancreatic cancer.
Based on our data of 14 immunologically assessable
patients, the 1 mg dose of peptide in the vaccine emul-
sion led to the maximal T cell response. A dose response
between the vaccine peptide dose and an induced T cell
response was observed, with 100% of patients in the 1 mg
arm who were eligible for immunologic evaluation dem-
onstrating a CD8+ T cell response by IFN-γ ELISPOT.
The median OS and PFS were 334 and 56 days, respect-
ively, and the vaccination was safe and well tolerated. We
believe that the randomized phase I trial design proved to
be a useful tool, as it allowed determination of the optimal
dose of peptide for induction of an antigen-specific CD8+
T cell response in this patient population.
Our study does have a number of limitations that
highlight some important issues in cancer vaccine devel-
opment. First, although our sample size was sufficient to
answer the primary scientific objective, it was not large
enough to have meaningful comparisons of clinical out-
comes among the three groups. Also, no obvious correl-
ation between a positive ELISPOT response and clinical
outcome was noted, but this is not unexpected due to
known resistance mechanisms in the tumor microenvi-
ronment and the study’s small sample size. Second, due
to the inherent need for HLA-A2 restriction that is
imposed by using a peptide antigen, many potential sub-
jects were screen failures. In that regard, vaccination
platforms that do not restrict based on HLA status, such
as those based on whole protein or full length cDNAs
incorporated into suitable vectors, do have advantages.
Third, CEA is not necessarily utilized by pancreatic can-
cer cells as part of the malignant process, and it could
be argued that gene products contributing to cancer cell
growth or survival may be more desirable to target.
Finally, in order to enable sufficient accrual, we did not
have a homogenous patient population, allowing the
inclusion of metastatic, resected, and locally advanced
patients, thus not permitting definitive conclusions to be
made about any one group.
Of note, two patients in group A were enrolled into
the study with NED and failed to develop an immune
response. We do not have alternate indices of general
immune competence for them to try to further explain
their anergic state, but the stimulation with PMA +
Figure 3 ELISPOT kinetics of in vitro primed CAP-1 peptide specific-CD8+ T cell responses. T cell responses for all 14 patients at various
time points on the trial are presented and stratified by treatment arm. Day 1 is first day of vaccination.
γ
γ
Figure 2 Baseline and Peak ELISPOT results for 14 evaluable patients and median and mean CAP1-6D (Panel A) and wild-type (Panel B)
T Cell response per dose level. Baseline (blue diamond) and peak (green triangle) T cell responses by ELISPOT for each of the 14 evaluable
patients. Median and mean T cell response by ELISPOT (spots per 104 CD8+ cells) measured after at least 3 cycles is indicated by the orange bars
per each arm. For CAP1-6D (Panel A) median/mean Arm A (0.01 mg) response = 10.5/36.5; median/mean Arm B (0.1 mg) response = 51.75/148.45;
median/mean Arm C (1 mg) response = 270.63/247.69. P = 0.028 as measured by Mann–Whitney Rank Sum Test comparing medians. For
wild-type (Panel B) median/mean Arm A (0.01 mg) response = 3/22.05; median/mean Arm B (0.1 mg) response = 81/120.5; median/mean Arm C
(1 mg) response = 222.5/188.5. P = 0.028 as measured by Mann–Whitney Rank Sum Test comparing medians.
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Table 3 Grade 2 or greater toxicities associated with
vaccine
Grade 1 Grade 2 Grade 3 Grade 4
Toxicity No. (%) No. (%) No. (%) No. (%)
Injection-site reaction 11 (53) 1 (5) 0 (0) 0 (0)
Erythema 9 (47)






Reaction NOS 1 (5)
Toxicity unrelated to injection
site
10 (53) 3 (16) 4 (21) 0 (0)
Pain 10 (53) 3 (16) 2 (11)
Fatigue 10 (53) 1 (5) 4 (21)
Anorexia 4 (21) 0 (0) 2 (11)
Nausea/Vomiting 8 (42) 0 (0) 1 (5)
Constipation 6 (32) 2 (11) 1 (5)
Diarrhea 3 (16) 1 (5) 1 (5)















A M Y SD 8 3.7 9.4
A M N PD 4 1.8 15.9
A M N SD 24 11.1 47.2*
A NED N SD 24 12.4 32.4*
A NED N SD 24 12.2 31.9*
B M Y PD 4 1.9 3.1
B M Y SD 23 12 43.2*
B M Y PD 3 1.4 3.6
B M N SD 22 10 ?*
B M N PD 4 1.8 2.2
B M NE PD 1 0.3 0.4
B M NE PD 4 1.2 1.5
B M NE PD 4 1.8 3.0
C M Y PD 4 1.9 11.3
C LA Y CR 81 39.3 75.4*
C M Y PD 4 1.8 11.0
C M Y SD 12 6.2 48.5*
C M NE PD 3 1.2 2.0
C M NE PD 3 1.4 2.6
Abbreviations: NED = No evidence of disease; M =metastatic; LA = locally
advanced; Y = Yes; N = No; NE = not evaluable; * = currently alive; ? = patient is
known to be alive but had withdrawn consent; Data as of May 22, 2012.
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in Figure 3, the kinetics of the T cell response suggest
that if a response occurred, it happened early with the
maximum response occurring within the first 100 days.
For those on trial for over 4 months, the response does
appear to wane over time, although was sustained at
over 300 days for two patients. Also, in regard to
vaccine-site delayed-type hypersensitivity as evidenced
by skin reactions we did not notice a particular pattern
to correlate with ELISPOT results. Out of the 11
patients with a reaction, some developed it without ever
mounting a positive ELISPOT results, some at the time
of their peak and some at a different point in time.
Three phase III trials of PC vaccines have been
conducted previously, all of which did not meet their
primary objective [31-33]. Over 20 vaccine immunother-
apy clinical trials are currently ongoing in various stages
of completion (http://clinicaltrials.gov) examining vary-
ing iterations of the above approaches for cancers in-
cluding but not limited to PC, including novel peptides
(e.g., mesothelin, VEGFR1/VEGFR2 and survivin), DNA-
based vaccines, and combinations of vaccines with
chemotherapy. Most results in PC thus far have been
underwhelming and the field is still searching for the op-
timal vaccine approach, clinical context, and predictivebiomarkers of clinical benefit. Nonetheless, the favorable
clinical outcome observed in a subset of patients treated
in our current CEA vaccine trial motivates continued
investigations of immunotherapeutic strategies in this
disease.
Our vaccination approach utilized the adjuvant
Montanide ISA-51 along with the cytokine GM-CSF
included in the emulsion. It is not clear that this is an
optimal vaccine adjuvant for peptide vaccines, and fur-
ther improvements in the vaccine formulation are con-
ceivable. After this trial was initiated, Slingluff and
colleagues reported that the inclusion of GM-CSF with
Montanide may result in diminished peptide-induced T
cell responses in a melanoma vaccine study [34]. The
TLR agonists CpG 7909 and polyIC:LC have recently
been explored and should continue to be investigated as
a possible adjuvant [35]. The MAGE-3 protein-based
vaccine from GSK-Bio utilizes a combination of the
TLR9 agonist CpG7909 and the TLR4 agonist MPL [36].
Other cytokines with immune-potentiating activities
could be considered, including IL-12 [37-39]. Thus,
while our study has identified an optimal dose of CEA
peptide, further improvements in vaccine potency might
be achievable through optimization of the adjuvant
component.
In addition to utilizing vaccination to increase the fre-
quency of tumor-reactive T cells, features of the tumor
microenvironment can be dominantly suppressive and it
may be necessary to inhibit such factors for optimal clinical
Geynisman et al. Journal for ImmunoTherapy of Cancer 2013, 1:8 Page 9 of 10
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as IL-10 and TGF-β; expression of indoleamine-2,3-
dioxygenase; the presence of myeloid-derived suppressor
cells (MDSCs) and regulatory T cells (Tregs); inhibitory li-
gands such as B7-H1/PD-L1; and the dense tumor stroma
that is characteristic of this disease [40,41]. Recently, using
an agonist CD40 mAb in combination with gemcitabine,
Beatty et al. demonstrated a partial reversal of immune
suppression in PC and highlighted the role of macro-
phages in this process [42]. Future studies combining an
optimized vaccine formulation along with manipulations
to favorably alter the PC tumor microenvironment will be
attractive to consider.
Conclusions
We conducted a randomized phase I trial of carcinoem-
bryonic antigen (CEA) peptide (CAP1-6D)/Montanide/
GM-CSF-vaccine in 19 pancreatic cancer patients. Our
primary objective was to find the optimal dose of the vac-
cine. The dose that induced a maximal T cell response
was 1 mg and no significant toxicity was observed. Several
long-term survivors with metastatic or locally advanced
disease were noted. Future studies can build on these
results by combining the above vaccine peptide dose with
stronger adjuvants and/or agents to favorably alter the
tumor microenvironment.
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